Novo Nordisk launches oral Wegovy treatment

Statements (3)

1. ▲ Bullish

   Novo Nordisk is likely to see its stock price rise due to the Danish central bank doubling the nation's growth forecast, driven by increased U.S. demand for its weight loss drugs.

   fortune.comSep 23, 2026 11:09 UTC
2. ▼ Bearish

   Novo Nordisk shares are likely to continue sliding due to the surprise miss on Wegovy's performance, which is expected to impact the pharmaceutical sector.

   marketwatch.comAug 4, 2026 20:17 UTC
3. ▲ Bullish

   Novo Nordisk is getting a boost from its new Wegovy weight-loss pill that is holding onto its lead against Eli Lilly's more recently launched Foundayo.

   japantimes.co.jpAug 3, 2026 07:36 UTC